Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Hepatitis B Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

103 recruiting trials for Hepatitis B. Eligibility criteria explained in plain English.

TrialFinderData lists 103 Hepatitis B clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 32% (13 studies); the largest phase groups are Phase 2: 13, Phase 1: 11, Phase 4: 7, Phase 3: 6.

Research is led by Third Affiliated Hospital, Sun Yat-Sen University (7), Assistance Publique - Hôpitaux de Paris (4), University Hospital, Limoges (4), among the most active sponsors registered for these trials.

The most frequently studied intervention is HRS-5635 Injection (drug, 5 trials), followed by Peg-IFN, No intervention.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
103
Total Trials
103
Recruiting Now
6
Phase 3 Trials
10
Sponsors

Track Hepatitis B trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 2NCT05304234

Liver Cancer Disparities in American Indian and Alaska Native Persons

We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP...

Sponsor: University of WashingtonEnrolling: 2001 location
RECRUITINGNCT07589985

Hep Mec Cohort in Zambia

Observational cohort of adults with acute and chronic hepatitis B infection in Zambia, with and without HIV coinfection. Participants join the study at the time of diagnosis and...

Sponsor: University of Alabama at BirminghamEnrolling: 3903 locations
RECRUITINGNCT06947356

Comparison of TAF and TDF in Preventing Mother-to-Child Transmission of HBV in Pregnancies With High Viral Loads

The main objective of this study is to compare the mother-to-infant transmission rates of hepatitis B between pregnant women receiving treatment with tenofovir alafenamide and...

Sponsor: Guangzhou 8th People's HospitalEnrolling: 21010 locations
RECRUITINGPhase 1NCT07342881

Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in...

This is a Phase 1 non-randomized, open-label, single-dose study of pevifoscorvir sodium (also known as ALG-000184) in participants with severe renal impairment (Part 1), in...

Sponsor: Aligos TherapeuticsEnrolling: 302 locations
RECRUITINGNCT07240350

The Role and Regulatory Mechanism of Germinal Center Immune Response in Hepatitis B Virus Infection

The purpose of this observational study is to investigate the structure and composition of germinal centers in individuals with chronic HBV infection. The primary questions it...

Sponsor: Nanfang Hospital, Southern Medical UniversityEnrolling: 2801 location
RECRUITINGPhase 3NCT07090759

To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B...

This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial, aiming to evaluate the efficacy and safety of GST-HG141 in patients with...

Sponsor: Fujian Akeylink Biotechnology Co., Ltd.Enrolling: 5261 location
RECRUITINGPhase 2NCT07370207

Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region

This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated...

Sponsor: AusperBio Therapeutics Inc.Enrolling: 848 locations
RECRUITINGPhase 3NCT06413121

Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV

In 2012, the World Health Assembly (WHA) endorsed the proposed Polio Endgame Strategy, which includes withdrawal of the Sabin-virus type 2 antigen-responsible for an estimated 95%...

Sponsor: Serum Institute of India Pvt. Ltd.Enrolling: 15579 locations
RECRUITINGNCT03825458

Creation of a Cohort for the Quantitation and Characterization of Circulating Viral RNAs as a New Biomarker of...

The " CirB-RNA " cohort aims to create a biological collection associated with clinical and biological data from patients with hepatitis B infection. This project is part of a...

Sponsor: Hospices Civils de LyonEnrolling: 35006 locations
RECRUITINGPhase 4NCT04588077

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized...

Sponsor: Mercy Medical CenterEnrolling: 2001 location
RECRUITINGNCT04166266

National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses

This is a multicentre observational study with prospective and retrospective data collection and retrospective data collection and biological collection from patients with HBV/HDV...

Sponsor: ANRS, Emerging Infectious DiseasesEnrolling: 80020 locations
RECRUITINGNCT06623071

Accupower ® HBV Performance Evaluation Quant Kit Bioneer Existation FA 96/384

As part of the CE marking of a hepatitis B diagnostic kit, the South Korean manufacturer Bioneer wishes to set up a performance study in France in accordance with the IVDR (RE...

Sponsor: CerbaXpertEnrolling: 452 locations
RECRUITINGNCT06876467

Study of the Cellular Response Induced After Vaccination Against the Hepatitis B Virus

296 million people worldwide are infected with the hepatitis B virus (HBV), despite the existence of an effective prophylactic vaccine. Current treatments (nucleoside analogues...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 1151 location
RECRUITINGPhase 1NCT04745403

Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)

This is a single center, single arm and open-label study to determine the safety of mRNA modified HBV-TCR redirected T-cells and to analyze the changes in tumor microenvironment...

Sponsor: Lion TCR Pte. Ltd.Enrolling: 101 location
RECRUITINGNCT06023056

Hepatitis B Vaccination After Neonatal Surgery

At present, whether the hepatitis B vaccine (HBV) can be vaccinated on time after neonatal surgery has become a common problem for children's families, neonatal surgeons, and...

Sponsor: Children's Hospital of Chongqing Medical UniversityEnrolling: 1801 location
RECRUITINGPhase 3NCT07343778

A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis

This is a single-arm, multicenter, open-label Phase III clinical trial to evaluate the safety and tolerability of high-dose hydronidone capsules in patients with hepatic fibrosis...

Sponsor: Beijing Continent Pharmaceutical Co, Ltd.Enrolling: 3001 location
RECRUITINGNCT04310787

Long-term Prognosis of Patients With Hepatitis B Related Acute-on-chronic Liver Failure

This study is to investigate the long-term outcomes and prognostic risk factors in patients recovered from hepatitis B virus related acute on-chronic liver failure.

Sponsor: Third Affiliated Hospital, Sun Yat-Sen UniversityEnrolling: 3001 location
RECRUITINGNCT04231565

Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.

This study is to investigate the clinical efficacy and safety of Nucleoside (acid) analogues treatment in patients with normal Alanine Aminotransferase and positive Hepatitis B...

Sponsor: Third Affiliated Hospital, Sun Yat-Sen UniversityEnrolling: 2001 location
RECRUITINGPhase 3NCT07307586

A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic...

Through regular monitoring of viral load, liver function and immune cell activity, the long-term efficacy of Adefovir in controlling HBV is precisely evaluated. By employing a...

Sponsor: Zhigang RenEnrolling: 1201 location
RECRUITINGPhase 3NCT05686759

A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.

The purpose of this study is to evaluate the efficacy and safety of undiluted intravenous infusion of I.V.-Hepabig inj. in post-liver transplant patients

Sponsor: GC Biopharma CorpEnrolling: 1058 locations
RECRUITINGNCT06904820

Acceptability and Feasibility of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users and...

The "Scanvir" concept aims to achieve barriers to HCV screening and treating of marginalized patients. The concept is applicable to other various populations and territories and...

Sponsor: University Hospital, LimogesEnrolling: 23001 location
RECRUITINGNCT06550622

Improved Sensitivity Detection of Serum HBsAg and HBsAg Reversion

The goal of this observational study is to learn about the HBsAg reversion rate at 48 weeks off treatment in HBsAg-negative patients by HBsAg NEXT assay which has improved...

Sponsor: Huashan HospitalEnrolling: 3001 location
RECRUITINGPhase 1NCT06668727

Safety and Antiviral Activity of a Monoclonal Hepatitis B Antibody (The SAMBA Study)

Hepatitis B virus (HBV) remains a major global health problem with an estimated 257 million people living with the infection worldwide. Chronic HBV (CHB) is a major cause of liver...

Sponsor: Aarhus University HospitalEnrolling: 301 location
RECRUITINGNCT05195450

TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With...

The main goal of therapy for patients with chronic HBV infection with no significant liver disease is to improve survival and quality of life by preventing disease progression,...

Sponsor: Institute of Liver and Biliary Sciences, IndiaEnrolling: 2001 location
RECRUITINGPhase 2NCT07069569

A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs

This is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of AHB-137 injection in combination with other hepatitis B drugs in participants...

Sponsor: Ausper Biopharma Co., Ltd.Enrolling: 2001 location
RECRUITINGNCT06323681

Pegylated Interferon α in Previously Interferon-treated CHB(Leading Study)

Previous clinical practice and exploratory studies suggest that some patients who have not achieved functional cure in the first round of interferon therapy can achieve HBsAg...

Sponsor: Qing XIeEnrolling: 20161 location
RECRUITINGNCT07169656

Observation Study on Reducing the Risk of Liver Cancer Associated With Hepatitis B (Zhiyuan) Project.

This study is a multicenter, prospective, observational real-world study designed to investigate and analyze the current treatment patterns of chronic hepatitis B (CHB) across 200...

Sponsor: The First Affiliated Hospital of Zhengzhou UniversityEnrolling: 1500020 locations
RECRUITINGPhase 1 / Phase 2NCT06513286

TherVacB - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate

This study is an open-label, ascending dose phase 1b/2a trial to assess the safety and immunogenicity of a heterologous protein prime/MVA boost therapeutic hepatitis B vaccine in...

Sponsor: Michael HoelscherEnrolling: 816 locations
RECRUITINGNCT06966908

Hospital-Based Management of Patients With Chronic Hepatitis B Virus Infection

Since 2022, the Third Affiliated Hospital of Sun Yat-sen University has initiated the "Hot Wave Project", a comprehensive hepatitis B infection prevention and management system...

Sponsor: Third Affiliated Hospital, Sun Yat-Sen UniversityEnrolling: 163003 locations
RECRUITINGPhase 1NCT05856890

HepB mAb19 in Individuals With Chronic Hepatitis B Infection

This is a first-in-human, placebo-controlled, single dose, dose-escalation phase 1 study to evaluate the safety, pharmacokinetics and antiviral activity of a highly potent...

Sponsor: Rockefeller UniversityEnrolling: 372 locations
RECRUITINGNCT06874127

Non-Invasive Model for Fibrosis Regression in HBV Patients

A total of 1000 chronic hepatitis B (CHB) patients with liver biopsy performed at least 1 year after antiviral therapy are retrospectively enrolled. All the patients received NAs...

Sponsor: Beijing Friendship HospitalEnrolling: 11001 location
RECRUITINGNCT05361603

Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures

The principle is to propose dedicated monthly screening days bringing together the health personnel involved (hepatologist, addictologist, nurse in charge of the program,...

Sponsor: University Hospital, LimogesEnrolling: 15001 location
RECRUITINGNCT02995252

The HOPE Study: Characterizing Patients With Hepatitis B and C

This is an observational, longitudinal, prospective study for sample collection and evaluation for future therapy or disease progression of chronic hepatitis B and C. Participants...

Sponsor: University of Maryland, BaltimoreEnrolling: 5502 locations
RECRUITINGPhase 1NCT06062966

The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)

End-stage heart failure (HF) is a progressive illness with a mortality rate similar to most advanced cancers.Roughly 5% of patients with HF have end-stage disease that is...

Sponsor: Virginia Commonwealth UniversityEnrolling: 201 location
RECRUITINGNCT05466565

Antiviral Therapy for Patients With Liver Cancer After Surgery

This is a single-center, prospective, observational, real world study designed to evaluate the effects of peginterferon α-2b(pegabin) combined with nucleoside (acid) analogs...

Sponsor: Xiangya Hospital of Central South UniversityEnrolling: 3601 location
RECRUITINGPhase 4NCT03792919

Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK)

To Identify the collected cases who can stop NAs safely with satisfactory clinical outcome including sustain viral remission and HBsAg clearance among chronic hepatitis B(CHB)...

Sponsor: Humanity & Health Medical Group LimitedEnrolling: 20001 location
RECRUITINGNCT05051098

A Non-interventional Registry for Patients with Hepatitis B Virus Infection

In order to tackle the unmet needs in chronic HBV infection, a consortium of clinical partners has gathered to establish a registry for patients with hepatitis B mono- and...

Sponsor: Hannover Medical SchoolEnrolling: 30001 location
RECRUITINGPhase 1 / Phase 2NCT07200193

A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B

This is an open-label study with single- and multiple-ascending dose arms followed by a dose expansion arm. The primary objective of the study is to determine the safety and...

Sponsor: nChroma BioEnrolling: 664 locations
RECRUITINGNCT05951751

The TRIple Elimination Model Of Mother-to-child Transmission Program (TRI-MOM)

The TRI-MOM program aims to implement and evaluate a simplified (based on inexpensive rapid diagnostic tests), integrated (in governmental health facilities) and coordinated...

Sponsor: Institut de Recherche pour le DeveloppementEnrolling: 28002 locations
RECRUITINGPhase 1NCT07275918

SA1211 Injection Phase 1 Study

The goal of this clinical trial is to evaluate the safety, tolerability, immunogenicity and Pharmacokinetics (PK) characteristics of SA1211 Injection in healthy volunteers (Part...

Sponsor: Suzhou Siran Biotechnology Co.,Ltd.Enrolling: 801 location
RECRUITINGNCT04597164

Combination of DPMAS and Low Volume PE for Patients With HBV Related ACLF

This study is to investigate investigate the safety and efficacy of Double plasma molecular adsorption system with sequential low-dose plasma exchange in treating hepatitis B...

Sponsor: Third Affiliated Hospital, Sun Yat-Sen UniversityEnrolling: 2001 location
RECRUITINGNCT07257562

Combined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance

The goal of this prospective observational study is to determine the effects of concomitant administration of Bacteroides fragilis and Branched-Chain Amino Acids on hepatitis B...

Sponsor: First Affiliated Hospital of Fujian Medical UniversityEnrolling: 401 location
RECRUITINGPhase 4NCT05182463

Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

There are about 400 million chronic hepatitis B virus (HBV) infection patients worldwide, posing a serious threat to global public health security. In China, HBV infection occured...

Sponsor: Third Affiliated Hospital, Sun Yat-Sen UniversityEnrolling: 50001 location
RECRUITINGNCT04896255

Long-term Outcomes of Anti-viral Therapies in Patients With Chronic Viral Hepatitis B

The goal of this observational, multicenter , real-world study is to evaluate the long-term outcomes of different antiviral therapies in adults with chronic hepatitis B (CHB). The...

Sponsor: Huashan HospitalEnrolling: 330001 location
RECRUITINGNCT07491848

Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D

Periodontal disease is a chronic inflammatory condition associated with systemic diseases, highlighting the concept of periodontal medicine. This study aims to investigate the...

Sponsor: Research Center of Periodontal-Systemic InteractionsEnrolling: 252 locations
RECRUITINGNCT03097952

"Real-life" Cohort Study on Patients With Chronic HBV Infection in Jiangsu

Hepatitis B virus (HBV) infection remains one of the most serious health problems worldwide. Patients with chronic HBV infection are at an increased risk for developing hepatic...

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolEnrolling: 200006 locations
RECRUITINGNCT04690972

"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and...

Development of preclinical translational models for chronic liver tumors and diseases study, such as spheroids cultured in autologous medium and murine xenograft models to test...

Sponsor: Institut National de la Santé Et de la Recherche Médicale, FranceEnrolling: 8001 location
RECRUITINGPhase 2NCT06092333

VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B

Background: Chronic hepatitis B virus (HBV) infection affects 292 million people worldwide; 887,000 die each year from cirrhosis, liver cancer, and related issues. Treatment...

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Enrolling: 501 location
RECRUITINGNCT06906016

New HBV Infection Biomarkers: Clinical Characterization and Impact on Management

Chronic Hepatitis B Virus (HBV) infection affects nearly 300 million people worldwide and is a leading cause of liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). In...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 9001 location
RECRUITINGPhase 2NCT05769816

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained...

Hepatitis B virus (HBV) infection is a major public health threat in China. At present, a functional cure, also known as clinical cure or sustained Hepatitis B surface antigen...

Sponsor: The Second Affiliated Hospital of Chongqing Medical UniversityEnrolling: 1201 location

Showing 50 of 103 trials.Search all Hepatitis B trials

Frequently Asked Questions

There are currently 103 clinical trials for Hepatitis B, with 103 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Hepatitis B, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 6 Phase 3 trials for Hepatitis B, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.